These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 1727687)

  • 21. Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important role in mediating canine coronary thrombosis by regulating platelet glycoprotein IIb/IIIa activation.
    Katoh A; Ikeda H; Murohara T; Haramaki N; Ito H; Imaizumi T
    Circulation; 1998 Dec 22-29; 98(25):2891-8. PubMed ID: 9860792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
    Beaughard M; Brasset M; John G; Massingham R
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):577-83. PubMed ID: 8569218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries.
    Ikeda H; Koga Y; Oda T; Kuwano K; Nakayama H; Ueno T; Toshima H; Michael LH; Entman ML
    J Am Coll Cardiol; 1994 Dec; 24(7):1749-56. PubMed ID: 7963124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
    Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M
    J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
    Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain.
    McGhie AI; McNatt J; Ezov N; Cui K; Mower LK; Hagay Y; Buja LM; Garfinkel LI; Gorecki M; Willerson JT
    Circulation; 1994 Dec; 90(6):2976-81. PubMed ID: 7994845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries.
    Anderson HV; McNatt J; Clubb FJ; Herman M; Maffrand JP; DeClerck F; Ahn C; Buja LM; Willerson JT
    Circulation; 2001 Nov; 104(19):2331-7. PubMed ID: 11696474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries.
    Yao SK; Ober JC; Krishnaswami A; Ferguson JJ; Anderson HV; Golino P; Buja LM; Willerson JT
    Circulation; 1992 Oct; 86(4):1302-9. PubMed ID: 1394936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Kern K; Tilton GD; Apprill P; Ashton J; Schmitz J; Buja LM; Willerson JT
    Circ Res; 1984 Nov; 55(5):642-52. PubMed ID: 6488486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators.
    Golino P; Ashton JH; Buja LM; Rosolowsky M; Taylor AL; McNatt J; Campbell WB; Willerson JT
    Circulation; 1989 Jan; 79(1):154-66. PubMed ID: 2910540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of monoclonal antibody to P-selectin and analogue of sialyl Lewis X on cyclic flow variations in stenosed and endothelium-injured canine coronary arteries.
    Ueyama T; Ikeda H; Haramaki N; Kuwano K; Imaizumi T
    Circulation; 1997 Mar; 95(6):1554-9. PubMed ID: 9118525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclic flow variations in a conscious dog model of coronary artery stenosis and endothelial injury correlate with acute ischemic heart disease syndromes in humans.
    Ikeda H; Koga Y; Kuwano K; Nakayama H; Ueno T; Yoshida N; Adachi K; Park IS; Toshima H
    J Am Coll Cardiol; 1993 Mar; 21(4):1008-17. PubMed ID: 8450149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Buja LM; Tilton GD; Willerson JT
    Circulation; 1984 Jun; 69(6):1161-70. PubMed ID: 6546902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors.
    Apprill P; Schmitz JM; Campbell WB; Tilton G; Ashton J; Raheja S; Buja LM; Willerson JT
    Circulation; 1985 Aug; 72(2):397-405. PubMed ID: 2988822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraplatelet tetrahydrobiopterin plays an important role in regulating canine coronary arterial thrombosis by modulating intraplatelet nitric oxide and superoxide generation.
    Kanaya S; Ikeda H; Haramaki N; Murohara T; Imaizumi T
    Circulation; 2001 Nov; 104(20):2478-84. PubMed ID: 11705828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD; Müller TH
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
    Weber AA; Reimann S; Schrör K
    Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombin is an important mediator of cyclic coronary blood flow variations due to platelet aggregation in stenosed canine coronary arteries.
    Eidt JF; Allison P; Noble S; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
    Trans Assoc Am Physicians; 1988; 101():125-36. PubMed ID: 3269674
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.